Log in

NASDAQ:AMRNAmarin Competitors & Alternatives

$6.98
+0.06 (+0.87 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.88
Now: $6.98
$7.05
50-Day Range
$6.59
MA: $6.94
$7.73
52-Week Range
$3.95
Now: $6.98
$26.12
Volume4.07 million shs
Average Volume11.32 million shs
Market Capitalization$2.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.72

Competitors

Amarin (NASDAQ:AMRN) Vs. RDY, ELAN, IONS, MYL, ACAD, and PRGO

Should you be buying AMRN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amarin, including Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), and Perrigo (PRGO).

Dr.Reddy's Laboratories (NYSE:RDY) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Dr.Reddy's Laboratories has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

12.9% of Dr.Reddy's Laboratories shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 2.0% of Dr.Reddy's Laboratories shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Dr.Reddy's Laboratories and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr.Reddy's Laboratories$2.32 billion3.78$259 million$2.7918.95
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71

Dr.Reddy's Laboratories has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Dr.Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dr.Reddy's Laboratories and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr.Reddy's Laboratories11.15%19.83%13.13%
Amarin-3.67%-4.05%-2.45%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Dr.Reddy's Laboratories and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr.Reddy's Laboratories01302.75
Amarin05802.62

Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Dr.Reddy's Laboratories.

Summary

Dr.Reddy's Laboratories beats Amarin on 8 of the 14 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Elanco Animal Health has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

44.4% of Amarin shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Elanco Animal Health and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion2.83$67.90 million$1.0620.53
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71

Elanco Animal Health has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-0.42%6.10%3.85%
Amarin-3.67%-4.05%-2.45%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Elanco Animal Health and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health04602.60
Amarin05802.62

Elanco Animal Health currently has a consensus price target of $29.20, suggesting a potential upside of 34.19%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Elanco Animal Health.

Summary

Amarin beats Elanco Animal Health on 8 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

84.0% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ionis Pharmaceuticals and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion7.54$303.26 million$2.0829.22
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71

Ionis Pharmaceuticals has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals16.79%12.50%6.41%
Amarin-3.67%-4.05%-2.45%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ionis Pharmaceuticals and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals17802.44
Amarin05802.62

Ionis Pharmaceuticals currently has a consensus price target of $74.8571, suggesting a potential upside of 23.17%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Amarin on 9 of the 13 factors compared between the two stocks.

Mylan (NASDAQ:MYL) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

Mylan has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Institutional & Insider Ownership

85.5% of Mylan shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 0.6% of Mylan shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mylan and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mylan$11.50 billion0.72$16.80 million$4.423.60
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71

Mylan has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Mylan, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mylan and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mylan0.54%20.00%7.49%
Amarin-3.67%-4.05%-2.45%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Mylan and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mylan06602.50
Amarin05802.62

Mylan currently has a consensus price target of $23.75, suggesting a potential upside of 49.09%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Mylan.

Summary

Mylan beats Amarin on 8 of the 14 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Amarin (NASDAQ:AMRN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Volatility and Risk

ACADIA Pharmaceuticals has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ACADIA Pharmaceuticals and Amarin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011502.94
Amarin05802.62

ACADIA Pharmaceuticals currently has a consensus price target of $56.50, suggesting a potential upside of 5.23%. Amarin has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than ACADIA Pharmaceuticals.

Valuation & Earnings

This table compares ACADIA Pharmaceuticals and Amarin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million24.68$-235,260,000.00($1.60)-33.56
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71

Amarin has higher revenue and earnings than ACADIA Pharmaceuticals. Amarin is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.8% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ACADIA Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-64.99%-39.40%-34.53%
Amarin-3.67%-4.05%-2.45%

Summary

Amarin beats ACADIA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Risk & Volatility

Amarin has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Amarin and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin05802.62
Perrigo04402.50

Amarin currently has a consensus price target of $17.2308, suggesting a potential upside of 146.86%. Perrigo has a consensus price target of $58.4286, suggesting a potential upside of 5.68%. Given Amarin's stronger consensus rating and higher probable upside, analysts plainly believe Amarin is more favorable than Perrigo.

Valuation and Earnings

This table compares Amarin and Perrigo's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million6.26$-22,650,000.00($0.07)-99.71
Perrigo$4.84 billion1.56$146.10 million$4.0313.72

Perrigo has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

44.4% of Amarin shares are owned by institutional investors. Comparatively, 83.9% of Perrigo shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amarin and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-3.67%-4.05%-2.45%
Perrigo3.77%9.72%4.93%

Summary

Perrigo beats Amarin on 8 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dr.Reddy's Laboratories logo
RDY
Dr.Reddy's Laboratories
0.9$52.88+1.1%$8.68 billion$2.32 billion32.24Analyst Downgrade
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.5$21.76+2.5%$8.58 billion$3.07 billion-1,088.00
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$60.78+0.0%$8.50 billion$1.12 billion55.25
Mylan logo
MYL
Mylan
1.6$15.93+1.1%$8.23 billion$11.50 billion132.76
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.5$53.69+3.9%$8.04 billion$339.08 million-33.98Analyst Upgrade
Perrigo logo
PRGO
Perrigo
1.9$55.29+0.2%$7.52 billion$4.84 billion40.36
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.7$151.88+0.6%$7.43 billion$14.98 million-28.50Heavy News Reporting
Bausch Health Companies logo
BHC
Bausch Health Companies
2.5$19.00+3.5%$6.70 billion$8.60 billion-3.54Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.0$111.20+1.3%$6.11 billion$2.16 billion23.12Increase in Short Interest
SDGR
PPD
0.9$92.82+0.2%$5.88 billionN/A0.00
United Therapeutics logo
UTHR
United Therapeutics
1.7$119.04+1.1%$5.30 billion$1.45 billion9.93Analyst Downgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$160.43+1.6%$5.25 billion$26.52 million-16.30
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.5$86.04+1.6%$5.13 billion$103.71 million-11.71Insider Selling
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
0.9$116.36+0.5%$5.11 billion$3.34 million-17.93
Zai Lab logo
ZLAB
Zai Lab
1.1$82.30+1.5%$4.71 billion$12.98 million-27.16
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.4$44.20+0.1%$4.50 billion$168.80 million491.17
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$85.77+2.0%$4.47 billion$1.11 billion65.98Heavy News Reporting
Myokardia logo
MYOK
Myokardia
1.4$92.24+2.0%$4.39 billion$33.56 million-13.83
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.6$79.32+0.2%$4.29 billion$66.51 million-10.68Insider Selling
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.8$23.98+1.9%$4.19 billion$114.62 million-9.19
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.3$71.56+0.5%$4.17 billionN/A-5.67
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$67.83+3.8%$4.13 billion$2.11 million-13.93Increase in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55+0.3%$4.07 billion$182.24 million-11.96Insider Selling
Heavy News Reporting
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.8$126.53+0.9%$3.93 billion$311.33 million129.11
FibroGen logo
FGEN
FibroGen
2.1$43.13+0.9%$3.88 billion$256.58 million-32.67
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$54.85+1.5%$3.84 billion$117.91 million-9.34
HUTCHISON CHINA/S logo
HCM
HUTCHISON CHINA/S
1.0$28.53+3.2%$3.81 billion$204.89 million-35.66
BBIO
BridgeBio Pharma
1.6$29.76+1.9%$3.61 billion$40.56 million-12.00Insider Selling
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$57.84+0.3%$3.59 billion$36.13 million-53.06Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$54.07+2.0%$3.47 billion$306.98 million-10.84
Allakos logo
ALLK
Allakos
1.1$66.90+0.6%$3.26 billionN/A-33.62
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.51+0.6%$3.18 billion$806.43 million-9.83
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.5$55.07+3.0%$3.17 billion$25 million-12.21Analyst Downgrade
Insider Selling
Increase in Short Interest
Heavy News Reporting
Alkermes logo
ALKS
Alkermes
1.1$19.59+0.9%$3.11 billion$1.17 billion-22.26
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
2.2$80.97+3.6%$3.08 billionN/A-31.63
Insmed logo
INSM
Insmed
1.5$29.57+1.3%$2.99 billion$136.47 million-10.49
KRTX
Karuna Therapeutics
1.5$100.92+8.7%$2.87 billionN/A-0.69Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$67.45+0.1%$2.58 billion$644.77 million10.61Decrease in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$30.81+7.0%$2.49 billionN/A-4.91Increase in Short Interest
Opko Health logo
OPK
Opko Health
1.7$3.76+5.9%$2.37 billion$901.90 million-7.83Increase in Short Interest
TPTX
Turning Point Therapeutics
1.2$64.35+0.2%$2.31 billionN/A-17.87
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$43.01+0.8%$2.27 billion$6.87 million-3.45
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$20.45+1.8%$2.24 billion$150,000.00-10.07
IGMS
IGM Biosciences
1.5$70.82+2.2%$2.21 billionN/A-14.75
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.6$52.37+1.5%$2.21 billion$421.03 million-2,617.19Analyst Report
Heavy News Reporting
Uniqure logo
QURE
Uniqure
1.7$44.81+1.6%$2.02 billion$7.28 million-14.89
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.72+2.8%$1.91 billion$306.49 million19.00
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$49.27+2.5%$1.90 billion$26.69 million-37.33Analyst Upgrade
Heavy News Reporting
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.78+0.4%$1.90 billion$23.90 million-15.25Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.4$32.82+2.7%$1.87 billion$156.70 million-30.67
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.